Skip to main content

Table 1 TERT promoter mutations, BRAF V600E mutation and ALK rearrangement in 243 Korean patients with thyroid cancer

From: Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation

  Patient TERT promoter mutation BRAF V600E ALK rearrangement
C228T C250A C250T Overall
WDTC without distant metastasis 192 0 0 0 0 142 (74 %) 0
 PTC, classic 127 0 0 0 0 110 (87 %) 0
 PTC, classic with TCF 11 0 0 0 0 10 (91 %) 0
 PTC, EFV 9 0 0 0 0 1 (11 %) 0
 PTC, IFV 7 0 0 0 0 5 (71 %) 0
 PTC, tall cell 16 0 0 0 0 15 (94 %) 0
 PTC, oncocytic 1 0 0 0 0 1 (100 %) 0
 PTC, Warthin-like 1 0 0 0 0 0 0
 FTC, minimally invasive 20 0 0 0 0 0 0
WDTC with distant metastasis 30 10 (33 %) 0 2 (7 %) 12 (40 %) 15 (50 %) 0
 PTC, classic 14 3 (21 %) 0 0 3 (21 %) 7 (50 %) 0
 PTC, classic with TCF 4 2 (50 %) 0 1 (25 %) 3 (75 %) 4 (100 %) 0
 PTC, EFV 1 0 0 0 0 0 0
 PTC, macrofollicular 1 0 0 0 0 0 0
 PTC, tall cell 5 4 (80 %) 0 0 4 (80 %) 3 (60 %) 0
 PTC, columnar cell 1 0 0 1 (100 %) 1 (100 %) 1 (100 %) 0
 PTC, diffuse sclerosing 1 0 0 0 0 0 0
 FTC, minimally invasive 2 1 (50 %) 0 0 0 0 0
 FTC, widely invasive 1 0 0 0 1(100 %) 0 0
Poorly differentiated carcinoma 7 1 (14 %) 1 (14 %) 0 2 (29 %) 1 (14 %) 0
Anaplastic carcinoma 5 2 (40 %) 0 1 (20 %) 3 (60 %) 4 (80 %) 0
Medullary carcinoma 9 0 0 0 0 0 0
  1. WDTC well-differentiated thyroid carcinoma, PTC papillary thyroid carcinoma, TCF tall cell features, EFV encapsulated follicular variant, IFV infiltrative follicular variant, FTC follicular thyroid carcinoma